By Kate Kelland
LONDON, May 20 (Reuters) - India's export ban on COVID-19
shots risks dragging the battle against the pandemic "back to
square one" unless wealthy nations step in to plug a gaping hole
in the COVAX global vaccine-sharing scheme, health specialists
said on Thursday.
COVAX, which is critical for poorer countries, relies on
AstraZeneca shots made by the Serum Institute of India,
the world's biggest maker of vaccines. It was already around 100
million doses short of where it had planned to be when India
halted exports a month ago amid a surge in infections there.
Rich countries with plentiful COVID-19 vaccine stocks must
now share them immediately, at scale, the global experts said,
otherwise the pandemic could be prolonged as the world struggles
to contain a virus that is continuing to spread and mutate.
"It is a huge concern," said Anna Marriott, health policy
manager at the global charity Oxfam. She and others said it was
imperative that wealthy countries and regions make good on their
rhetoric and share excess vaccines now.
"The current approach that relies on a few pharma monopolies
and a trickle of charity through COVAX is failing - and people
are dying as a result."
Reuters reported on Tuesday that India is extending its ban,
meaning it is now unlikely to resume major exports before
October.
Will Hall, global policy manager for the Wellcome global
health trust, said COVAX's heavy reliance on the Serum Institute
left it vulnerable. India's extension of its export ban made it
even more crucial for rich countries to share doses via the
scheme, he said, "not in six months' time, not in a month's
time, but now".
"We're not going to beat this virus unless we think and act
globally," he added. "We all should be concerned about this –
the more the virus continues to spread, the greater the risk of
it mutating to a stage where our vaccines and treatments no
longer work. If that happens we're back to square one."
A highly transmissible new variant of the novel coronavirus
first identified in India has spread to several countries around
the world.
'VERY FEW OPTIONS'
COVAX aims to get vaccines to at least 20% of the
populations of the more-than 90 low and middle-income countries
signed up to receive the shots as donations. It has so far
distributed about 65 million doses of mainly the AstraZeneca
COVID-19 vaccine, many of them to Africa.
A spokeswoman for the GAVI vaccines alliance, which co-leads
COVAX, said the facility was working hard to make up supplies.
"We're trying to find different ways of making sure that
those countries that have received the first dose are able to
also receive a second dose and that vaccinations can continue,"
she told Reuters. "What we need right now, to meet the immediate
needs, is dose sharing."
The United States said on Wednesday it would share a total
of 20 million doses of Pfizer's, Moderna's and Johnson &
Johnson's vaccines by the end of June, donating a
significant amount via COVAX, on top of 60 million AstraZeneca
shots it had already planned to give to other countries.
EU trade commissioner Valdis Dombrovskis said this week that
the bloc was working to significantly ramp up vaccine donations
through COVAX in the second half of 2021. Vaccine sharing
announced by EU member states has so far amounted to 11.1
million vaccines, he said, of which 9 million are being shared
via COVAX.
Britain, meanwhile, will have enough surplus doses to fully
vaccinate at least 50 million people in poorer countries once
every adult at home has been fully vaccinated, according to
analysis by UNICEF's UK office last week.
The GAVI spokeswoman said COVAX'S reliance on the Serum
Institute was based, largely, on its vast production capacity,
ability to deliver at low cost and on assurances that it would
be able to produce the millions of doses needed at speed.
"It always was COVAX's plan to grow and diversify its
portfolio to 10-12 vaccines but at the start of the year when
approved vaccines were only slowly coming online, we had very
few options available to us," she said.
(Reporting by Kate Kelland; Additional reporting by Francesco
Guarascio in Brussels and Ludwig Burger in Frankfurt; Editing by
Pravin Char)
Astrazeneca (AZN)
